Use of polymyxins for carbapenem-resistant infections in children and adolescents

Carolina Barco-Cabrera¹, Yeison A. Reina¹, Diana M. Dávalos²,³, Pio López¹,², Rubén Tulcán-Toro⁴, Erika Cantor²,⁵ and Eduardo López-Medina ¹,²,⁶*

¹Department of Pediatrics, Universidad del Valle, Calle 13 #100-00 Cali, Colombia; ²Centro de Estudios en Infectología Pediátrica, Calle 5B5 #37 bis-28 Cali, Colombia; ³Public Health Department, Universidad Icesi, Calle 18 #122-135 Cali, Colombia; ⁴Health Science Department, Universidad de Nariño, Calle 18 carrera 50 Pasto, Colombia; ⁵Universidad de Valparaíso, Blanco 951 Valparaíso, Chile; ⁶Clínica Imbanaco Grupo Quirónsalud, Carrera 38 BIS #5B2-04 Cali, Colombia

*Corresponding author. E-mail: eduardo.lopez@ceiponline.org
@edu_lopezmed

Received 18 January 2022; accepted 10 June 2022

Background: Polymyxins are still used in children in some regions due to limited availability of newer antibiotics.

Objectives: To describe our experience in a cohort of children who received polymyxins for suspected or confirmed carbapenem-resistant bacterial infections (CRI), and explore potential factors associated with therapeutic success.

Methods: Retrospective, observational study in children and adolescents <18 years who received IV polymyxin B or colistin therapy for suspected or culture-documented CRI and were admitted to a high complexity clinic in Cali, Colombia between 1 September 2016 and 22 June 2020. Patients’ demographic, clinical and microbiologic characteristics were collected and analysed; associations with therapeutic success were explored using univariate and multivariate models.

Results: There were 40 episodes of polymyxin use (polymyxin B, n=34; colistin, n=6) in 34 patients with a median age of 10 years (IQR 7–15); 65% were male. There were 17 adverse events: 3 (17.6%) neurotoxic and 14 (82.4%) nephrotoxic. Therapeutic success was achieved in 28 episodes (70%), of which 32% (9/28) had adverse events. Therapeutic success decreased by 35% with each additional year of age (OR 0.65; 95% CI 0.49–0.80) and by 7% for every hour that elapsed between the onset of fever and the start of appropriate antibiotic therapy (OR 0.93; 95% CI 0.8–0.97) and increased with concomitant non-carbapenem treatment (OR 6.87; 95% CI 1.04–71.01) and the use of adequate empirical therapy (OR 121.36; 95% CI 2.90–1147.95).

Conclusions: Several factors were associated with the therapeutic success of polymyxins, however, more than half of episodes had therapeutic failure or adverse events. Antibiotics with greater efficacy and safety are needed in regions with high rates of CRI.

Introduction

Gram-negative infections resistant to carbapenems pose a public health and clinical challenge, especially in critically ill or immunosuppressed patients. Although novel antibiotics such as ceftazidime/avibactam, a combination of a third-generation cephalosporin and a new synthetic β-lactamase inhibitor, may be used as a therapeutic option, widespread access to these novel antibiotics, especially in low- or middle-income countries, remains restricted due to limited availability and high costs. Thus, clinical use of polymyxins (colistin [polymyxin E] and polymyxin B) play an important role as salvage therapy for otherwise untreatable Gram-negative infections resistant to carbapenems. However, therapeutic outcomes associated with polymyxin use in children are not fully understood, with studies limited to small retrospective case series following colistin treatment, without insights into factors associated with therapeutic success or failure. The lack of data in children on polymyxin’s effectiveness, appropriate dosing regimens, and associated toxicities poses a challenge to paediatric infectious
disease specialists. We describe our experience in a cohort of children receiving polymyxins for suspected or confirmed carbapenem-resistant bacterial infections (CRI), and explore potential factors associated with therapeutic success.

Materials and methods

A retrospective, observational study was conducted in a cohort of children and adolescents aged up to 18 years admitted to any hospital ward at Clínica Imbanaco in Cali, Colombia, and who received therapy with IV polymyxins (polymyxin B or colistin) due to suspected or culture-documented CRI between 1 September 2016 and 22 June 2020. Clínica Imbanaco is a referral hospital where children with the most complex acute or chronic conditions receive care. During the study period, all inpatient blood and urine cultures with Gram-negative isolates were identified by VITEK® MS (bioMérieux, Marcy-l’Étoile, France). Susceptibility testing was performed according to the manufacturer’s recommendations using AST271 for urine samples and AST272 for blood culture samples in the VITEK® 2XL system (bioMérieux).

Suspected CRI was reported for patients who had a previous infection with a carbapenem-resistant bacterium, were colonized with it and developed a hospital-acquired infection following more than 7 days of carbapenem exposure in the previous 6 weeks. Patients with suspected CRI had a systemic inflammatory response syndrome, negative cultures and other microbiological studies during the current episode, and a clinical focus of infection documented on physical examination (pneumonia, colitis, etc.) or without source (i.e. culture-negative sepsis).

Demographic, clinical, and microbiological characteristics of patients were collected and analysed. We described episodes where colistin or polymyxin B were administered for at least 72 h. For patients with recurrent infections, more than one treatment episode was considered, provided that the patient was asymptomatic for at least 15 days and their cultures became negative between treatment episodes.

Therapeutic success was defined as clearance of bacteraemia and/or resolution of signs and symptoms of the index infection without the need for additional antibiotics to treat the isolated microorganism 30 days after therapy. Empirical antibiotic therapy was considered appropriate if the isolate displayed in vitro susceptibility to any systemic antibiotic administered. In suspected infections (not culture-confirmed), empirical antibiotic therapy was considered appropriate when the antibiotic administered achieved therapeutic success. Safety was assessed through the evaluation of adverse events occurring during polymyxin use. The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury (AKI) was used to classify AKI.6 Neurotoxicity was defined as any neurological sign or symptom during polymyxin use without an alternative explanation. Definitions of hospital-acquired infections and of specific types of infections were according to criteria from CDC.7

Because of the small sample size, a Bayesian logistic regression model with weakly informative prior, using a normal distribution, was adjusted to identify the factors related to therapeutic success. A Hamiltonian Monte Carlo algorithm was used to simulate samples from the posterior distributions for the model parameters. Variables were selected based on their posterior predictive checks, according to Bayesian criteria using leave-one-out cross-validation (LOO) and the widely applicable information criterion (WAIC). Results were confirmed under the frequentist approach using a logistic regression model estimated by the maximum likelihood procedure. A backward elimination algorithm was performed to identify covariates associated independently with therapeutic success.

Associations with therapeutic success were explored using univariate and multivariate models, reporting ORs with respective 95% CI for logistic and Bayesian models. An association was considered statistically significant when a P value <0.05 was observed under the frequentist approach and when the unit was not found within the credible interval (OR=1) under the Bayesian approach. The Bayesian model was carried out in R using the rstanarm package and the logistic model in Stata 16.0 (StataCorp, College Station, TX, USA). A sensitivity analysis, including only culture-confirmed CRI, was performed.

Results

There were 40 episodes of polymyxin use (34 with polymyxin B and 6 with colistin) in 34 patients with a median age of 10 years (IQR 7–15); 65% were male. The most frequent comorbidity was ALL (35.3% [12/34]); 65% (22/34) of patients had a history of HSCT.

All infections were hospital acquired. Bloodstream infections accounted for half of all episodes (20/40) and the most frequent aetiologic microorganisms were Klebsiella pneumoniae (27.5% [11/40]) and Pseudomonas aeruginosa (27.5% [11/40]). Antimicrobial susceptibilities of the detected isolates are shown in Table S1 (available as Supplementary data at JAC-AMR Online). For 10 (25%) infection episodes, polymyxins were used due to suspected CRI (pneumonia, n=4; enterocolitis, n=3; osteomyelitis, culture-negative sepsis and central nervous system infection, n=1 each) (Table 1). Polymyxins were administered concomitantly with other Gram-negative acting antimicrobial agents in all cases (double therapy in 47.5% [19/40] and triple therapy in 52.5% [21/40]). Meropenem was used in 28 (70.0%) episodes, of which 18 (64.3%) had culture-documented CRI (78% [14/18] with MIC ≥16 mg/L). The median doses of polymyxin and colistin used were 25 000 IU/kg/day and 4 mg of colistin base activity/kg/day, respectively, and the median duration of therapy with both polymyxins was 8.5 days (IQR 7–12.5). Appropriate empirical antibiotic therapy was administered in 28 (70.0%) episodes. A median time of 15 h (IQR 2–66) elapsed between onset of fever and the beginning of appropriate antibiotic therapy.

There were 17 adverse events that occurred during polymyxin use: 14 (82.4%) nephrotoxic (4 that induced drug suspension or reduction of the dosage) and 3 (17.6%) neurotoxic. Ten nephrotoxic events were KDIGO stage one and 4 were KDIGO stage three. Two neurological events were paraesthesias—of the hands and feet, and perioral; and one was behavioural changes not related to the infection under treatment or any other alternative explanation. The median duration of kidney injury was 12 days (IQR 4.8–23.8). Overall, at least one concomitant nephrotoxic agent was used in 92.5% (37/40) of treatment episodes. The median total duration of fever was 4.5 days (IQR 1–10). ICU was required in 15 (37.5%) episodes with a median length of stay of 16 days (IQR 5–28). There were five deaths in total, four of them infection related.

Therapeutic success was achieved in 70% (28/40) of episodes; of which 32% (9/28) had adverse events. In Bayesian multivariate analysis (Table 2), for each additional year of age increase, the probability of obtaining therapeutic success decreased by 35% (OR 0.65; 95% CI 0.49–0.80). For every hour that elapsed between the onset of fever and the start of appropriate antibiotic therapy according to antibiogram, the probability of therapeutic success decreased by 7% (OR 0.93; 95% CI 0.88–0.97). The use of adequate empirical therapy increased the chance of therapeutic success (OR 121.36; 95% CI 2.90–1147.95), as did concomitant treatment with non-carbapenems (OR 6.87; 95% CI 1.04–71.01). Sensitivity analysis including only patients with
Table 1. Clinical characteristics of episodes with polymyxin treatment according to therapeutic outcome

| Variables                                | Total (n=40) | Therapeutic failure (n=12) | Therapeutic success (n=28) |
|------------------------------------------|--------------|---------------------------|----------------------------|
| Age, years, median (IQR)                | 10.0 (7.0–15.0) | 15.0 (10.7–16.0)         | 9.0 (4.7–13.0)          |
| Sex, male, n (%                        | 28 (70.0)    | 9 (75.0)                  | 19 (67.9)               |
| Type of insurance, n (%)                |              |                           |                           |
| Contributive                            | 25 (62.5)    | 6 (50.0)                  | 19 (67.9)               |
| Subsidized                               | 15 (37.5)    | 6 (50.0)                  | 9 (32.1)                |
| Comorbidities, n (%)                    |              |                           |                           |
| ALL                                      | 15 (37.5)    | 7 (58.3)                  | 8 (28.6)                |
| AML                                      | 9 (22.5)     | 2 (16.7)                  | 7 (25.0)                |
| Aplastic anaemia                         | 7 (17.5)     | 3 (25.0)                  | 4 (14.3)                |
| Chronic diseases                         | 3 (7.5)      | 0 (0.0)                   | 3 (10.7)                |
| Other conditions<sup>a</sup>             | 6 (15.0)     | 0 (0.0)                   | 6 (21.4)                |
| History of HSCT, n (%)                  | 28 (70.0)    | 10 (83.3)                 | 18 (64.3)               |
| HSCT phase, n (%)                        |              |                           |                           |
| Conditioning                             | 13 (32.5)    | 2 (16.7)                  | 11 (39.3)               |
| Pre-engraftment                          | 7 (17.5)     | 2 (16.7)                  | 5 (17.9)                |
| Engraftment to 100 days post-transplant  | 11 (27.5)    | 2 (16.7)                  | 9 (32.1)                |
| >100 post-transplant days                | 9 (22.5)     | 6 (50.0)                  | 3 (10.7)                |
| Infection site, n (%)                    |              |                           |                           |
| Bloodstream infection                    | 20 (50)      | 6 (50)                    | 14 (50)                 |
| No bloodstream infection<sup>b</sup>     | 20 (50)      | 6 (50)                    | 14 (50)                 |
| Microbiological isolation, n (%)         |              |                           |                           |
| *P. aeruginosa*                          | 10 (25)      | 3 (25)                    | 7 (25)                  |
| *K. pneumoniae*                          | 10 (25)      | 1 (8.3)                   | 9 (32.1)                |
| *Escherichia coli*                       | 4 (10)       | 1 (8.3)                   | 3 (10.7)                |
| Polymicrobial infection<sup>c</sup>      | 3 (7.5)      | 1 (8.3)                   | 2 (7.1)                 |
| *Pseudomonas spp.*                       | 2 (5)        | 1 (8.3)                   | 1 (3.5)                 |
| *Klebsiella spp.*                        | 1 (2.5)      | 0                         | 1 (3.5)                 |
| None                                     | 10 (25)      | 5 (41.6)                  | 5 (17.9)                |
| Appropriate empirical antibiotic therapy, n (%)<sup>d</sup> | 28 (70) | 9 (75) | 19 (67.9) |
| Time from fever to appropriate antibiotic therapy, h, median (IQR) | 15 (2–66) | 24 (7.5–69) | 4.0 (2–72) |
| Concomitant Gram-negative treatment, n (%) | 28 (70) | 11 (91.7) | 17 (60.7) |
| Carbapenem                               |              |                           |                           |
| Not carbapenems                          | 12 (30)      | 1 (8.3)                   | 11 (29.3)               |
| Fosfomycin                               | 4            | 0                         | 4                       |
| Aminoglycosides                          | 3            | 0                         | 3                       |
| Ciproflaxcin                             | 2            | 1                         | 1                       |
| Tigecycline                              | 2            | 0                         | 2                       |
| Ceftazidime/avibactam                    | 1            | 0                         | 1                       |
| Meropenem MIC, mg/L, n (%)               |              |                           |                           |
| 8                                        | 4 (10)       | 1 (8.3)                   | 3 (10.7)                |
| ≥16                                      | 26 (65)      | 6 (50)                    | 20 (71.4)               |
| Concomitant nephrotoxic agent, n (%)     |              |                           |                           |
| None                                     | 3 (7.5)      | 1 (8.3)                   | 2 (7.1)                 |
| 1                                        | 20 (50)      | 3 (25)                    | 17 (60.7)               |
| ≥2                                       | 17 (42.5)    | 8 (66.7)                  | 9 (32.1)                |
| Neutrophil count, x 10<sup>3</sup> cells/mm<sup>3</sup>, median (IQR)<sup>e</sup> | 1.07 (0.03–3.06) | 0.96 (0.01–2.63) | 1.16 (0.05–4.09) |
| Platelet count, x 10<sup>9</sup> cells/mm<sup>3</sup>, median (IQR)<sup>e</sup> | 29.5 (13.25–110.75) | 18.5 (8.75–96.25) | 40.5 (13.25–115.75) |
| CRP, mg/dL, median (IQR)<sup>e</sup> | 83.7 (40.20–163.25) | 127 (72.27–221.25) | 60.85 (30.62–151.45) |
| Baseline GFR, n (%)<sup>f</sup>          |              |                           |                           |
| Normal                                   | 36 (90)      | 11 (91.7)                 | 25 (89.3)               |
| Abnormal                                 | 4 (10)       | 1 (8.3)                   | 3 (10.7)                |

CRP, C-reactive protein; GFR, glomerular filtration rate.
<sup>a</sup>Lymphoma, n = 2; hemophagocytic lymphohistiocytosis, n = 2; dendritic cell leukaemia, n = 2.
<sup>b</sup>Urinary tract infection, n = 10; pneumonia, n = 4; enterocolitis, n = 3; osteomyelitis, culture-negative sepsis and central nervous system infections, n = 1 each.
<sup>c</sup>*P. aeruginosa* and *Salmonella* group, *Pseudomonas putida* and *E. coli, K. pneumoniae* and *E. coli*.
<sup>d</sup>Appropriate empirical antibiotic therapy: administration of an antibiotic for the isolated or suspected bacteria to which it is susceptible.
<sup>e</sup>Obtained at time of diagnosis of infection.
documented CRI conﬁrmed the effect of age and concomitant treatment (Table S2). Six patients with recurrent infections had repeat courses of polymyxins and were no more likely to have treatment failures ($\chi^2 = 0.2, P = 0.64$).

**Discussion**

In our cohort of patients receiving polymyxin therapy, all with suspected or conﬁrmed CRI, therapeutic success was achieved in 70% (28/40) of episodes, however 32% (9/28) of these successes were associated with adverse events. Overall, 42.5% (17/40) of episodes had adverse events during polymyxin use, while 47.5% (19/40) of episodes had therapeutic success without drug toxicity. These data highlight the need to consider novel antibiotics to treat children with CRI.

The therapeutic success described here resembles previous studies, although we report a higher frequency of nephrotoxicity probably related to the higher use of concomitant nephrotoxic agents to treat malignant disorders or prevent graft versus host disease in HSCT recipients. Most patients in this cohort had received an HSCT, reflecting the extensive use of antibiotics these patients receive while treating their baseline condition, predisposing them to carbapenem-resistant infections, and highlighting the need to rationalize antibiotic use in children and adolescents with cancer.

In our study, we identiﬁed a series of factors independently associated with therapeutic success. Speciﬁcally, we identiﬁed that for each year of age increase, the odds of therapeutic success decrease by 35% for reasons that are unclear. Previously, it was reported that among children receiving polymyxin therapy, older age was associated with higher odds of developing nephrotoxicity. The use of concomitant therapy with non-carbapenem antibiotics was also associated with higher odds of therapeutic success. This observation is likely related to the high frequency of organisms with meropenem MIC $\geq 16$ mg/L, supporting the current recommendations to avoid the use of meropenem for CRI with MIC $>8$ mg/L.

---

**Table 2.** Logistic model of factors related to clinical success with polymyxin

| Variable                              | Frequentist approach, OR [95% CI]          | Bayesian approach, OR [95% CI]          |
|---------------------------------------|-------------------------------------------|----------------------------------------|
|                                       | univariate                  | multivariate                  | univariate                  | multivariate                  |
| Age, years                            | 0.78 [0.64–0.95]$^*$            | 0.65 [0.47–0.90]$^*$            | 0.78 [0.65–0.90]           | 0.65 [0.49–0.80]$^{a}$        |
| Sex                                   | Ref.                        | —                         | Ref.                        | —                             |
| History of HSCT                        | 0.70 [0.15–3.25]             | —                         | 0.67 [0.16–2.33]            | —                             |
| Comorbidities                          | 0.36 [0.06–1.98]             | —                         | 0.33 [0.06–1.25]            | —                             |
| Leukaemia                              | Ref.                        | —                         | Ref.                        | —                             |
| Appropriate empirical antibiotic therapy | 0.38 [0.08–1.73]             | —                         | 0.37 [0.09–1.26]            | —                             |
| Time from fever to appropriate antibiotic therapy, h | 1.42 [0.31–6.55] | 138.39 [1.23–15526.18]$^*$ | 1.53 [0.43–6.67] | 121.36 [2.90–11477.95]$^{a}$ |
| Infection site                         | Bloodstream infection        | Ref.                       | —                         | Ref.                        |
| Concomitant treatment                  | 1.00 [0.25–3.87]             | —                         | 1.00 [0.31–3.17]            | —                             |
| Carbapenems                            | Ref.                        | Ref.                      | Ref.                        | —                             |
| No carbapenems                         | 7.12 [0.80–63.16]$^{*}$      | 7.92 [0.87–0.98]$^{*}$      | 0.99 [0.98–1.01]            | 0.93 [0.88–0.97]$^{a}$        |
| Other nephrotoxic agents               | No                          | Ref.                      | —                         | Ref.                        |
| Yes                                   | 1.18 [0.10–14.42]            | 1.03 [0.06–9.96]            | —                         | —                             |
| Neutrophil count, $\times 10^3$ cells/mm$^3$ | 1.00 [0.99–1.00]             | 1.00 [0.99–1.00]            | —                         | —                             |
| Platelet count, $\times 10^3$ cells/mm$^3$ | 1.00 [0.99–1.01]             | 1.00 [0.99–1.01]            | —                         | —                             |
| CRP mg/dL                              | 0.99 [0.99–1.00]             | 0.99 [0.99–1.00]            | —                         | —                             |
| Basal GFR                              | Normal                      | Ref.                      | Ref.                        | —                             |
| Abnormal                               | 1.32 [0.12–14.14]            | 1.69 [0.23–26.28]           | —                         | —                             |
| Microbiological isolation              | None                        | —                         | 0.20 [0.04–0.78]            | —                             |
|                                      | Pseudomonas                  | 0.40 [0.73–2.24]            | 0.39 [0.09–1.73]            | —                             |
|                                      | Other pathogens              | Ref.                      | Ref.                        | —                             |

CRP, C-reactive protein; GFR, glomerular ﬁltration rate; Ref., reference value.

$^*P<0.05$.

$^aP<0.1$.

$^a$Credible interval does not contain the unit.
It has been reported that an inadequate empirical therapy, or a delay in the use of appropriate antibiotic therapy, is associated with higher mortality in adult patients.9,10 In our cohort, for each hour of delayed appropriate therapy, the odds of success decreased by 7%. Of concern, given the MDR nature of the pathogens, several infectious episodes in our study received an inappropriate empirical antibiotic. It is of paramount importance to identify risk factors for CRI in children and adolescents to increase the chances of providing early appropriate therapy.

This study has several limitations. First, this is a small cohort, which may have resulted in imprecise estimates from the model. The use of a Bayesian logistic regression model with confirmation under the frequentist approach was used to reduce this weakness. Second, it was a single-centre study preventing generalizability of results. Third, it does not include information about the specific mechanisms of carbapenem resistance, which may have impacted treatment outcomes. Fourth, for 10 episodes, polymyxins were used for suspected but not confirmed infections, which may have led to the inclusion of some patients without CRI, creating bias in the logistic models. However, suspected infections were only included when they had a high risk of CRI based on clinical and epidemiological data and such misclassification would have been non-differential for both outcome categories and therefore unlike-ly to have had a major effect on overall conclusions. In addition, we performed a sensitivity analysis including only culture-proven CRI, which confirmed the effect of younger age and non-carbapenem concomitant therapy as factors associated with clinical success. Finally, the sample size was small, and the data were collected retrospectively in very complex patients; however, the use of detailed definitions, the thorough review of medical charts and the use of a Bayesian logistic model in this study may have overcome these limitations.

Our study describes the characteristics of polymyxin or colis-tin treatment episodes in Colombia, and factors associated with their therapeutic success. However, many children and adolescents had therapeutic failure or adverse events, which is of relevance considering that newer antibiotics with better efficacy and safety are available for CRI.11–13 All children globally should have access to newer, safer and more effective drugs to treat CRI, including those from lower- and middle-income countries where these infections represent a growing health threat.

Funding
This study was carried out as part of our routine work.

Transparency declarations
The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Supplementary data
Tables S1 and S2 are available as Supplementary data at JAC-AMR Online.

References
1. Chiotos K, Han JH, Tamma PD. Carbapenem-resistant Enterobacteriaceae infections in children. Curr Infect Dis Rep 2016; 18: 2.
2. Tumbarello M, Trecarichi EM, Corona A et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019; 68: 355–64.
3. Sheu CC, Chang YT, Lin SY et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol 2019; 10: 80.
4. Tamma PD, Newland JG, Pannaraj PS et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013; 32: 17–22.
5. Karbuz A, Ozdemir H, Yaman A et al. The use of colistin in critically ill children in a pediatric intensive care unit. Pediatr Infect Dis J 2014; 33: e19–24.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1–138.
7. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309–32.
8. Chiotos K, Hayes M, Gerber JS et al. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc 2020; 9: 56–66.
9. Falcone M, Bassetti M, Tiseo G et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care 2020; 24: 29.
10. Kadri SS, Lai YL, Warner S et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021; 21: 241–51.
11. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 2019; 69(Suppl 7): S565–75.
12. Hakeam HA, Alsahl H, Albabtain L et al. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis 2021; 109: 1–7.
13. van Duin D, Lok JJ, Earley M et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66: 163–71.